跳至主要内容
临床试验/CTRI/2025/03/082497
CTRI/2025/03/082497尚未招募不适用

Efficacy Of Individualized Homoeopathic Medicine In Management Of Non Alcoholic Fatty Liver Disease With The Help of Homoeopathic Medical Repertory by Robin Murphy-An Open Interventional Prospective Clinical Study

Dr Shweta Verma1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年3月30日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Symptomatological assessment

研究概览

简要总结

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25%, and is a

primary cause of cirrhosis and hepatocellular cancer. NAFLD is a disease spectrum

that ranges from steatosis with or without moderate inflammation (non-alcoholic

fatty liver) to non-alcoholic steatohepatitis (NASH).The prevalence of the disease has been increased due to the changes of life style(decreased physical activity and alterations in dietary habits) and the increased

detection rate. Homeopathy is one of the most popular holistic systems of medicine. The selection of remedy is based upon the theory of individualization and symptoms

similarity by using holistic approach.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
20.00 Year(s) 至 50.00 Year(s)(—)
性别
All

入选标准

  • Ultrasonographically diagnosed cases of non alcoholic Fatty liver disease.
  • Non alcoholic patient aged between 20 to 50 years.
  • Those who have given consent.
  • Patient of both the sexes will be included.

排除标准

  • Chronic alcoholic Patients with history or positive serologic evidence of viral or autoimmune hepatitis, and Wilson’s disease will be excluded from this study.
  • ï‚· Subjects with history of drug intake known to result in liver enzyme elevation will be excluded.
  • ï‚· Patients with complications of hepatic steatosis like liver cirrhosis, hepatocellular carcinoma.
  • ï‚· Patients not willing to participate.
  • ï‚· Patient below 20 years and above 50 years of age.
  • ï‚· Pregnant and lactating women.
  • ï‚· Patient suffering with any life threatening illness.

结局指标

主要结局

Symptomatological assessment

时间窗: 2 weeks,12 weeks

次要结局

  • To compare the changes in BARD score at baseline & every 3 months of treatment(12 weeks , 24 weeks)

研究者

发起方
Dr Shweta Verma
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Shweta Verma

State National Homoeopathic Medical College And Hospital

研究点 (1)

Loading locations...

相似试验